BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21756557)

  • 1. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.
    Chaichana KL; Zaidi H; Pendleton C; McGirt MJ; Grossman R; Weingart JD; Olivi A; Quiñones-Hinojosa A; Brem H
    Neurol Res; 2011 Sep; 33(7):759-64. PubMed ID: 21756557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
    Sage W; Guilfoyle M; Luney C; Young A; Sinha R; Sgubin D; McAbee JH; Ma R; Jefferies S; Jena R; Harris F; Allinson K; Matys T; Qian W; Santarius T; Price S; Watts C
    J Neurooncol; 2018 Jan; 136(2):273-280. PubMed ID: 29139095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article.
    Chaichana KL; Chaichana KK; Olivi A; Weingart JD; Bennett R; Brem H; Quiñones-Hinojosa A
    J Neurosurg; 2011 Mar; 114(3):587-94. PubMed ID: 20887095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
    Zhang YD; Dai RY; Chen Z; Zhang YH; He XZ; Zhou J
    Turk Neurosurg; 2014; 24(5):639-45. PubMed ID: 25269031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
    Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
    Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
    Subach BR; Witham TF; Kondziolka D; Lunsford LD; Bozik M; Schiff D
    Neurosurgery; 1999 Jul; 45(1):17-22; discussion 22-3. PubMed ID: 10414561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
    Darakchiev BJ; Albright RE; Breneman JC; Warnick RE
    J Neurosurg; 2008 Feb; 108(2):236-42. PubMed ID: 18240917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
    Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
    J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation.
    Chaichana KL; Kone L; Bettegowda C; Weingart JD; Olivi A; Lim M; Quinones-Hinojosa A; Gallia GL; Brem H
    Neurol Res; 2015 Aug; 37(8):717-26. PubMed ID: 25916669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
    Della Puppa A; Lombardi G; Rossetto M; Rustemi O; Berti F; Cecchin D; Gardiman MP; Rolma G; Persano L; Zagonel V; Scienza R
    J Neurooncol; 2017 Jan; 131(2):331-340. PubMed ID: 27757721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
    Xing WK; Shao C; Qi ZY; Yang C; Wang Z
    Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
    Roux A; Aboubakr O; Elia A; Moiraghi A; Benevello C; Fathallah H; Parraga E; Oppenheim C; Chretien F; Dezamis E; Zanello M; Pallud J
    Neurosurg Rev; 2023 Jun; 46(1):140. PubMed ID: 37329341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
    Barr JG; Grundy PL
    Br J Neurosurg; 2012 Dec; 26(6):818-22. PubMed ID: 22715955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
    Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
    Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.